Geisinger Medical Laboratories Test Catalog

Order Display Name: Geisinger Epic Procedure Code Or ID CPT Code:  

EBV VIRAL CAPSID ANTIGEN IGM ANTIBODY

Geisinger Epic Procedure Code: LAB2231             Geisinger Epic ID: 14932
       

SPECIMEN COLLECTION
Specimen type:
 Serum
Preferred collection container:
Alternate Collection Container:
6 mL red-top (plain, non-serum separator) tube
Specimen required:
0.5 mL serum; minimum 0.2 mL
SPECIMEN PROCESSING
Specimen processing instructions:
Allow to clot. Centrifuge and submit 0.5 mL serum. 
Transport temperature:
 Refrigerated (preferred). Room temperature (stable 8 hours) or frozen specimen also acceptable.
Specimen stability:
 Room temperature: 8 hours. 2-8°C: 96 hours. Frozen: 6 months.
Rejection criteria:
 Stability exceeded or gross hemolysis.
TEST DETAILS
Interpretation guide:
Result
Interpretation
Negative Absence of detectable VCA IgM antibodies. If exposure to Epstein-Barr virus is suspected despite a negative finding, a second sample should be collected and tested no less than one to two weeks later.
Equivocal Suggest a second sample be collected and tested one to two weeks later.
Positive Presence of detectable VCA IgM antibodies. Specific IgM antibodies are usually detected in patients with recent primary infection and may be found in patients with reactivated infections. Other EBV serology assays should be performed to confirm EBV-associated infectious mononucleosis.

NOTE: This test is for the qualitative determination of IgM antibodies to EBV VCA.

CPT code(s):
 86665
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.  The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
Test includes:
 Antibody detection to EBVCA IgM.
Methodology:
Chemiluminescence
Synonyms:
EB-IgM, EBV IGM, EBVCAM
Epstein Barr IgM Antibody
Epstein Barr Virus IgM Antibodies to Viral Capsid
Clinical significance:
Epstein-Barr virus (EBV) is responsible for infectious mononucleosis (IM) and has also been implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV-VCA IgM antibodies typically appear within 4-6 weeks of infection with IM, peak concurrently with clinical onset of the disease, and decline within 2-3 months. A positive EBV-VCA IgM antibody in conjunction with clinical findings is indicative of an active or recent infection.
Doctoral Director(s:)
Hoi-Ying Elsie Yu PhD, DABCC, FADLM    
Review Date: 12/13/2022

Performing Locations

Geisinger Medical Center

Performing laboratory: Immunology
Technical Lead: Kathy Hurst
Frequency: Five days per week, 1st shift.
Performed STAT? No
Locations  |    Search  |    Site Map |   Contact Us
©2000-2023 Geisinger Health System.   All rights reserved.